| Remuneration components submitted for approval | Amounts allocated for the 2025 financial year or accounting valuation | Amounts paid in 2025 or accounting valuation | Description |
|---|---|---|---|
Remuneration components submitted for approval
|
Amounts allocated for the 2025 financial year or accounting valuation
|
Amounts paid in 2025 or accounting valuation
|
Description Pursuant to the criterion relating to gender balance in strategic positions, in order for all the free shares granted to fully vest to the beneficiaries at the end of the vesting period, the average gender quota in strategic positions must be a minimum of 40% of members that are the same gender. If this is not achieved, the grant is reduced. No shares will fully vest in relation to this criterion if the average representation of one of the genders is less than 35% over the vesting period. The grant of shares to Nicolas Hieronimus in 2025 represents 2.84% of the total number of ACAs granted to the 2,648 beneficiaries of this same Plan. In accordance with the authorisation of the General Meeting of 23 April 2024, this grant of shares does not represent more than 0.6% of the share capital, it being understood that the maximum amount granted to corporate officers may not represent more than 10% of the total amount of free shares that may be granted. No share subscription or purchase options or other long-term incentives have been granted to Nicolas Hieronimus in 2025. |
| Remuneration of Directors | Remuneration of Directors Amounts allocated for the 2025 financial year or accounting valuation €0 |
Remuneration of Directors Amounts paid in 2025 or accounting valuation Nicolas Hieronimus does not receive any remuneration for his office as a Director. |
|
| Benefits in addition to remuneration | Benefits in addition to remuneration Amounts allocated for the 2025 financial year or accounting valuation €0 |
Benefits in addition to remuneration Amounts paid in 2025 or accounting valuation Benefits in kind Nicolas Hieronimus benefits from the material resources needed for the performance of his office such as, for example, the provision of a car with a driver. These arrangements, which are strictly limited to professional use and exclude all private use, are not benefits in kind. |
|
Remuneration components submitted for approval €11,228.49 |
Amounts allocated for the 2025 financial year or accounting valuation Supplementary social protection schemes: defined contribution pension, employee benefit and healthcare schemes Nicolas Hieronimus continues to be treated in the same way as a senior executive during the term of his corporate office, which will allow him to continue to benefit from the supplementary social protection schemes and, in particular, the defined contribution pension scheme, and the employee benefit and healthcare schemes applicable to the Company’s employees. The amount of the pension resulting from the employer’s contributions for the defined contribution pension scheme will be deducted from the pension due in respect of the defined benefit pension in accordance with the provisions of this group scheme. The amount of the employer’s contributions to the employee benefit and healthcare schemes amounted to €3,927.93 (gross) in 2025, and the amount of the employer’s contribution to the defined contribution pension scheme amounted to €7,300.56 (gross). |
||
Pursuant to Article L. 22-10-34, I of the French Commercial Code, the General Meeting, voting with the quorum and majority required for Ordinary General Meetings, approves the information described in section I of Article L. 22‑10-9 of the French Commercial Code as presented in section 2.4.2 of the 2025 Universal Registration Document.
Pursuant to Article L. 22-10-34, II of the French Commercial Code, the General Meeting, voting in accordance with the quorum and majority conditions required for Ordinary General Meetings, approves the fixed and variable components of the total remuneration and benefits paid during financial year 2025 or allocated for that year to the Chairman, Jean-Paul Agon, as presented in section 2.4.2.3 of the 2025 Universal Registration Document.
